https://news.medxy.ai/mortality-and-morbidity-after-below-knee-amputation-in-diabetes-insights-from-a-25-year-english-cohort-study/Medxy AIen2026-09-17T09:55:39-07:00Mortality and Morbidity After Below-Knee Amputation in Diabetes: Insights from a 25-Year English Cohort Study https://news.medxy.ai/zh/sarcoidosis-insights-2/Medxy AIzh2026-09-17T09:54:48-07:00心脏结节病新启示：MYSTICS 全国登记研究揭示诊断、治疗与预后的关键差异 https://news.medxy.ai/ja/74609-2/Medxy AIja2026-09-17T09:54:28-07:00心臓サルコイドーシスの診断・治療・予後における重要な相違点 https://news.medxy.ai/vi/sarcoidosis-insights/Medxy AIvi2026-09-17T09:54:07-07:00Sarcoidosis tim: Những hiểu biết toàn quốc từ cơ sở dữ liệu MYSTICS về chẩn đoán, điều trị và kết cục https://news.medxy.ai/cardiac-sarcoidosis-nationwide-insights-into-diagnosis-management-and-outcomes-from-the-mystics-registry/Medxy AIen2026-09-17T09:53:45-07:00Cardiac Sarcoidosis: Nationwide Insights into Diagnosis, Management, and Outcomes from the MYSTICS Registry https://news.medxy.ai/zh/targeted-vitamin-d/Medxy AIzh2026-09-17T09:52:58-07:00靶向维生素D补充用于心肌梗死后：来自TARGET-D试验的启示 https://news.medxy.ai/ja/targeted-vitamin-d-post-mi/Medxy AIja2026-09-17T09:52:42-07:00心筋梗塞後の標的型ビタミンD補充をどう評価するか：TARGET-D試験からの示唆 https://news.medxy.ai/vi/target-d-vitamin/Medxy AIvi2026-09-17T09:52:20-07:00Bổ sung vitamin D theo mục tiêu sau nhồi máu cơ tim: Những phát hiện từ thử nghiệm TARGET-D https://news.medxy.ai/evaluating-targeted-vitamin-d-supplementation-post-myocardial-infarction-insights-from-the-target-d-trial/Medxy AIen2026-09-17T09:52:02-07:00Evaluating Targeted Vitamin D Supplementation Post-Myocardial Infarction: Insights from the TARGET-D Trial https://news.medxy.ai/zh/heart-failure-cardiomyopathy/Medxy AIzh2026-09-17T09:51:07-07:00心力衰竭与心肌病中循证医学与个体化医疗的衔接：在标准化与个体化之间寻求平衡 https://news.medxy.ai/ja/ebm-personalized-care/Medxy AIja2026-09-17T09:50:45-07:00心不全・心筋症診療におけるEBMと個別化医療の架け橋：標準化と個別化の最適なバランス https://news.medxy.ai/vi/evidence-based-care-heart-failure/Medxy AIvi2026-09-17T09:50:19-07:00Dung hòa y học dựa trên bằng chứng và y học cá thể hóa trong suy tim và bệnh cơ tim: Cân bằng giữa chuẩn hóa và cá thể hóa https://news.medxy.ai/bridging-evidence-based-and-personalized-medicine-in-heart-failure-and-cardiomyopathies-balancing-standardization-with-individualization/Medxy AIen2026-09-17T09:49:55-07:00Bridging Evidence-Based and Personalized Medicine in Heart Failure and Cardiomyopathies: Balancing Standardization with Individualization https://news.medxy.ai/zh/acute-coronary-syndrome-pathways/Medxy AIzh2026-09-17T09:49:11-07:00真实世界中疑似急性冠脉综合征的0/1小时与0/3小时高敏肌钙蛋白路径比较 https://news.medxy.ai/ja/acute-coronary-syndrome-strategies/Medxy AIja2026-09-17T09:48:52-07:00実臨床で検証した：急性冠症候群疑いに対する0/1時間と0/3時間の高感度トロポニン戦略の比較 https://news.medxy.ai/vi/troponin-timing-comparison/Medxy AIvi2026-09-17T09:48:33-07:000/1 giờ hay 0/3 giờ: so sánh các đường đi troponin độ nhạy cao trong thực hành thực tế ở người bệnh nghi hội chứng vành cấp https://news.medxy.ai/comparing-0-1-hour-vs-0-3-hour-high-sensitivity-troponin-pathways-for-suspected-acute-coronary-syndrome-in-real-world-practice/Medxy AIen2026-09-17T09:48:08-07:00Comparing 0/1-Hour vs 0/3-Hour High-Sensitivity Troponin Pathways for Suspected Acute Coronary Syndrome in Real-World Practice https://news.medxy.ai/zh/bivalirudin-vs-heparin/Medxy AIzh2026-09-17T09:47:16-07:00BRIGHT-4 试验新解：Bivalirudin 与肝素在 STEMI 原发性 PCI 中的疗效比较及出血风险分层获益 https://news.medxy.ai/ja/74570-2/Medxy AIja2026-09-17T09:46:59-07:00STEMIに対する一次PCIにおけるビバリルジンとヘパリンの有効性比較 https://news.medxy.ai/vi/bright-4-pci-stemi/Medxy AIvi2026-09-17T09:46:39-07:00BRIGHT-4: Bivalirudin hay heparin trong PCI nguyên phát cho STEMI? Lợi ích trên cả nhóm nguy cơ chảy máu thấp và cao https://news.medxy.ai/bivalirudin-versus-heparin-in-primary-pci-for-stemi-efficacy-across-low-and-high-bleeding-risk-patients-insights-from-the-bright-4-trial/Medxy AIen2026-09-17T09:46:19-07:00Bivalirudin Versus Heparin in Primary PCI for STEMI: Efficacy Across Low and High Bleeding Risk Patients – Insights from the BRIGHT-4 Trial https://news.medxy.ai/zh/spaceflight-heart-adaptation/Medxy AIzh2026-09-17T09:45:19-07:00长期航天飞行与模拟火星重力下的心脏适应：一项纵向观察研究的启示 https://news.medxy.ai/ja/74565-2/Medxy AIja2026-09-17T09:44:58-07:00長期宇宙飛行および火星重力模擬環境下における心臓の適応 https://news.medxy.ai/vi/space-adaptation-mars-gravity/Medxy AIvi2026-09-17T09:44:32-07:00Tim thích nghi thế nào với bay vũ trụ dài ngày và trọng lực Sao Hỏa mô phỏng? Góc nhìn từ một nghiên cứu quan sát theo dõi dọc https://news.medxy.ai/cardiac-adaptations-to-prolonged-spaceflight-and-simulated-martian-gravity-insights-from-a-longitudinal-observational-study/Medxy AIen2026-09-17T09:44:11-07:00Cardiac Adaptations to Prolonged Spaceflight and Simulated Martian Gravity: Insights from a Longitudinal Observational Study https://news.medxy.ai/zh/gut-serotonin-vagus/Medxy AIzh2026-09-17T09:02:17-07:00肠道5-羟色胺能迷走神经信号：连接肠道菌群与高血压管理的新机制 https://news.medxy.ai/ja/serotonin-vagus-hypertension/Medxy AIja2026-09-17T09:01:55-07:00腸管セロトニン作動性迷走神経シグナル：腸内微生物叢と高血圧管理を結ぶ新たな架け橋 https://news.medxy.ai/vi/serotonergic-vagus-gut/Medxy AIvi2026-09-17T09:01:29-07:00Tín hiệu phế vị serotonergic ở ruột: mắt xích mới giữa hệ vi sinh đường ruột và kiểm soát tăng huyết áp https://news.medxy.ai/intestinal-serotonergic-vagal-signaling-a-novel-link-between-gut-microbiota-and-hypertension-management/Medxy AIen2026-09-17T09:01:08-07:00Intestinal Serotonergic Vagal Signaling: A Novel Link Between Gut Microbiota and Hypertension Management https://news.medxy.ai/zh/weight-loss-uric-acid-control/Medxy AIzh2026-09-17T07:36:21-07:00超重或肥胖男性高尿酸血症的减重与尿酸控制：限能量DASH、限碳水化合物与低嘌呤饮食的比较 https://news.medxy.ai/comparing-calorie-restricted-dash-carbohydrate-restricted-and-low-purine-diets-for-weight-loss-and-serum-urate-control-in-men-with-hyperuricemia/Medxy AIen2026-09-17T07:34:58-07:00Comparing Calorie-Restricted DASH, Carbohydrate-Restricted, and Low-Purine Diets for Weight Loss and Serum Urate Control in Men with Hyperuricemia https://news.medxy.ai/zh/bridging-als-trust-gap/Medxy AIzh2026-09-16T10:10:19-07:00弥合 ALS 临床试验的可信度鸿沟：迈向更严谨、更审慎的治疗开发 https://news.medxy.ai/ja/74685-2/Medxy AIja2026-09-16T10:10:00-07:00ALS臨床試験における信頼性のギャップを埋める：より厳密かつ慎重な治療法開発に向けて https://news.medxy.ai/vi/als-test-reliability-gap/Medxy AIvi2026-09-16T10:09:40-07:00Lấp đầy khoảng cách về độ tin cậy trong thử nghiệm ALS: Hướng tới tính nghiêm ngặt và hoài nghi lớn hơn trong phát triển điều trị https://news.medxy.ai/zh/carotid-stenting-benefits/Medxy AIzh2026-09-16T10:08:30-07:00CREST-2揭示：颈动脉支架置入术可作为强化药物治疗的有效辅助手段，降低卒中风险 https://news.medxy.ai/ja/stroke-prevention-options/Medxy AIja2026-09-16T10:08:13-07:00脳卒中予防の新たな有力選択肢：CREST-2が示した頸動脈ステント留置術と集中的内科治療の意義 https://news.medxy.ai/vi/carotid-stent-prevention/Medxy AIvi2026-09-16T10:07:54-07:00Đặt stent động mạch cảnh nổi lên như một biện pháp bổ trợ đã được chứng minh trong phòng ngừa đột quỵ: Góc nhìn từ CREST-2 https://news.medxy.ai/carotid-artery-stenting-emerges-as-a-proven-adjunct-to-intensive-medical-therapy-in-stroke-prevention-insights-from-crest-2/Medxy AIen2026-09-16T10:07:36-07:00Carotid Artery Stenting Emerges as a Proven Adjunct to Intensive Medical Therapy in Stroke Prevention: Insights from CREST-2 https://news.medxy.ai/zh/korsakoff-syndrome/Medxy AIzh2026-09-16T10:06:48-07:00Korsakoff综合征：临床特征、脑影像学发现与死亡风险 https://news.medxy.ai/ja/korsakoff-syndrome-analysis/Medxy AIja2026-09-16T10:06:27-07:00Korsakoff症候群の臨床像・脳画像所見・死亡リスクを大規模コホートで解析 https://news.medxy.ai/vi/74666-2/Medxy AIvi2026-09-16T10:06:02-07:00Hội chứng Korsakoff: Đặc điểm lâm sàng, hình ảnh thần kinh và nguy cơ tử vong https://news.medxy.ai/korsakoff-syndrome-clinical-profiles-brain-imaging-insights-and-mortality-risks-in-a-large-cohort/Medxy AIen2026-09-16T10:05:41-07:00Korsakoff Syndrome: Clinical Profiles, Brain Imaging Insights, and Mortality Risks in a Large Cohort https://news.medxy.ai/zh/ivig-prednisone-imyopathy/Medxy AIzh2026-09-16T10:04:35-07:00IVIG联合泼尼松可显著加速新诊断特发性炎性肌病康复：随机临床试验解读 https://news.medxy.ai/ja/ivig-prednisone-efficacy/Medxy AIja2026-09-16T10:04:17-07:00新規診断の特発性炎症性筋疾患に対するIVIG併用プレドニゾンの有効性：ランダム化臨床試験からの知見 https://news.medxy.ai/vi/ivig-prednisone-treatment/Medxy AIvi2026-09-16T10:03:56-07:00IVIG phối hợp prednisone giúp phục hồi tốt hơn ở bệnh viêm cơ viêm vô căn mới chẩn đoán: Góc nhìn từ thử nghiệm lâm sàng ngẫu nhiên https://news.medxy.ai/ivig-plus-prednisone-enhances-recovery-in-newly-diagnosed-idiopathic-inflammatory-myopathies-insights-from-a-randomized-clinical-trial/Medxy AIen2026-09-16T10:03:36-07:00IVIG Plus Prednisone Enhances Recovery in Newly Diagnosed Idiopathic Inflammatory Myopathies: Insights from a Randomized Clinical Trial https://news.medxy.ai/zh/prediabetes-activity-benefits/Medxy AIzh2026-09-16T10:02:48-07:00前驱糖尿病表型不同，身体活动改善幅度也不同：来自随机对照试验合并分析的启示 https://news.medxy.ai/ja/prediabetes-activity-response/Medxy AIja2026-09-16T10:02:25-07:00前糖尿病のタイプで異なる身体活動反応：糖尿病予防介入のプール解析から見えた示唆 https://news.medxy.ai/vi/physical-activity-interventions/Medxy AIvi2026-09-16T10:01:57-07:00Đáp ứng hoạt động thể chất khác nhau với các can thiệp giảm nguy cơ đái tháo đường theo kiểu hình tiền đái tháo đường: Bằng chứng từ các thử nghiệm ngẫu nhiên có đối chứng phân tích gộp https://news.medxy.ai/differential-physical-activity-responses-to-diabetes-risk-reduction-interventions-according-to-prediabetes-phenotype-insights-from-pooled-randomized-controlled-trials/Medxy AIen2026-09-16T10:01:34-07:00Differential Physical Activity Responses to Diabetes Risk Reduction Interventions According to Prediabetes Phenotype: Insights from Pooled Randomized Controlled Trials https://news.medxy.ai/zh/sweden-pregnancy-diabetes/Medxy AIzh2026-09-16T10:00:30-07:00瑞典全国队列研究揭示妊娠期糖尿病中的社会不平等 https://news.medxy.ai/ja/swedish-pregnancy-diabetes/Medxy AIja2026-09-16T10:00:11-07:00スウェーデン全国コホートでみる妊娠糖尿病の社会的不平等 https://news.medxy.ai/vi/social-inequality-gestational-diabetes/Medxy AIvi2026-09-16T09:59:48-07:00Bất bình đẳng xã hội trong đái tháo đường thai kỳ: góc nhìn từ một nghiên cứu đoàn hệ toàn quốc tại Thụy Điển https://news.medxy.ai/social-inequalities-in-gestational-diabetes-insights-from-a-nationwide-swedish-cohort-study/Medxy AIen2026-09-16T09:59:24-07:00Social Inequalities in Gestational Diabetes: Insights from a Nationwide Swedish Cohort Study https://news.medxy.ai/zh/oxytocin-obesity-thyroid/Medxy AIzh2026-09-16T09:58:39-07:00催产素如何影响肥胖中的甲状腺功能与心理健康：一项8周临床试验的启示 https://news.medxy.ai/ja/oxytocin-obesity-effects/Medxy AIja2026-09-16T09:58:20-07:00肥満におけるオキシトシンの甲状腺機能・メンタルヘルスへの影響：8週間臨床試験からの知見 https://news.medxy.ai/vi/oxytocin-thyroid-mental-health/Medxy AIvi2026-09-16T09:57:58-07:00Oxytocin trong điều hòa chức năng tuyến giáp và sức khỏe tâm thần ở béo phì: Góc nhìn từ thử nghiệm lâm sàng 8 tuần https://news.medxy.ai/oxytocins-role-in-modulating-thyroid-function-and-mental-health-in-obesity-insights-from-an-8-week-clinical-trial/Medxy AIen2026-09-16T09:57:39-07:00Oxytocin’s Role in Modulating Thyroid Function and Mental Health in Obesity: Insights from an 8-Week Clinical Trial https://news.medxy.ai/ja/ai-mobile-health-impact/Medxy AIja2026-09-16T05:17:15-07:00AI搭載ゲーム化モバイルヘルスアプリが血圧管理に与える影響：マッチド患者コホート研究 https://news.medxy.ai/vi/ai-health-apps/Medxy AIvi2026-09-16T05:16:59-07:00Ứng dụng di động y tế có AI và trò chơi hóa cải thiện kiểm soát huyết áp trong một đoàn hệ bệnh nhân ghép cặp https://news.medxy.ai/impact-of-an-ai-powered-gamified-mobile-health-application-on-blood-pressure-control-in-a-matched-patient-cohort/Medxy AIen2026-09-16T05:16:45-07:00Impact of an AI-Powered Gamified Mobile Health Application on Blood Pressure Control in a Matched Patient Cohort https://news.medxy.ai/zh/community-health-empowerment/Medxy AIzh2026-09-16T05:16:12-07:00社区健康中心的赋能技术：突破障碍，回应照护管理患者的健康社会决定因素 https://news.medxy.ai/ja/74299-2/Medxy AIja2026-09-16T05:15:56-07:00地域保健センターにおけるエンパワーメント技術：障壁を克服し、ケアマネジメント対象患者の健康の社会的決定要因に対応する https://news.medxy.ai/vi/healthcare-support-technology/Medxy AIvi2026-09-16T05:15:39-07:00Công nghệ hỗ trợ tại trung tâm y tế cộng đồng: Vượt rào cản để giải quyết các yếu tố xã hội quyết định sức khỏe ở bệnh nhân được quản lý chăm sóc https://news.medxy.ai/enabling-technologies-in-community-health-centers-overcoming-barriers-to-address-social-determinants-of-health-in-care-managed-patients/Medxy AIen2026-09-16T05:15:23-07:00Enabling Technologies in Community Health Centers: Overcoming Barriers to Address Social Determinants of Health in Care-Managed Patients https://news.medxy.ai/zh/74294-2/Medxy AIzh2026-09-16T05:14:52-07:00何时开始美沙酮带药治疗：证据综合与对阿片类药物使用障碍管理的临床启示 https://news.medxy.ai/ja/methadone-home-use/Medxy AIja2026-09-16T05:14:32-07:00メサドン持ち帰り投与はいつ始めるべきか：エビデンス統合とオピオイド使用障害管理への臨床的示唆 https://news.medxy.ai/vi/methadone-treatment-start/Medxy AIvi2026-09-16T05:14:10-07:00Thời điểm khởi đầu methadone mang về nhà: Tổng hợp bằng chứng và hàm ý lâm sàng trong quản lý rối loạn sử dụng opioid https://news.medxy.ai/timing-of-initiation-of-methadone-take-home-dosing-evidence-synthesis-and-clinical-implications-for-opioid-use-disorder-management/Medxy AIen2026-09-16T05:13:50-07:00Timing of Initiation of Methadone Take-Home Dosing: Evidence Synthesis and Clinical Implications for Opioid Use Disorder Management https://news.medxy.ai/mindfulness-group-visits-a-new-approach-to-chronic-low-back-pain-relief/Medxy AIen2026-09-16T05:13:04-07:00Mindfulness Group Visits: A New Approach to Chronic Low Back Pain Relief https://news.medxy.ai/zh/digoxin-cardiovascular-outcomes/Medxy AIzh2026-09-16T05:12:27-07:00洋地黄苷对HFmrEF与HFrEF患者心血管结局的影响：证据综合分析 https://news.medxy.ai/ja/hfmref-hfrer-digitalis-effects/Medxy AIja2026-09-16T05:12:11-07:00HFmrEF・HFrEFにおけるDigitalis glycosidesの心血管転帰への影響：包括的エビデンスの統合 https://news.medxy.ai/vi/digitalis-glycosides-heart-failure/Medxy AIvi2026-09-16T05:11:54-07:00Digitalis glycosides và tác động lên kết cục tim mạch ở HFmrEF và HFrEF: Tổng hợp bằng chứng toàn diện https://news.medxy.ai/impact-of-digitalis-glycosides-on-cardiovascular-outcomes-in-hfmref-and-hfref-a-comprehensive-evidence-synthesis/Medxy AIen2026-09-16T05:11:38-07:00Impact of Digitalis Glycosides on Cardiovascular Outcomes in HFmrEF and HFrEF: A Comprehensive Evidence Synthesis https://news.medxy.ai/zh/atg-vs-alemtuzumab-aml/Medxy AIzh2026-09-16T05:09:43-07:00ATG 与 alemtuzumab 在 AML 同种异体移植 GvHD 预防中的比较：来自 EBMT 登记研究的启示 https://news.medxy.ai/ja/aml-gvhd-prevention/Medxy AIja2026-09-16T05:09:29-07:00AML同種移植におけるGvHD予防：ATGとalemtuzumabをEBMTレジストリで比較 https://news.medxy.ai/vi/alemtuzumab-gvhd-prevention/Medxy AIvi2026-09-16T05:09:11-07:00ATG hay Alemtuzumab: lựa chọn nào tối ưu để dự phòng GvHD trong ghép allo-HCT cho AML? https://news.medxy.ai/atg-versus-alemtuzumab-for-gvhd-prophylaxis-in-aml-allo-hct-insights-from-the-ebmt-registry/Medxy AIen2026-09-16T05:08:54-07:00ATG versus Alemtuzumab for GvHD Prophylaxis in AML Allo-HCT: Insights from the EBMT Registry https://news.medxy.ai/zh/graft-versus-host-disease-prevention/Medxy AIzh2026-09-16T05:08:20-07:00AML与MDS减低强度配型供者移植后GVHD预防如何优化：PTCy与ATG策略的新启示 https://news.medxy.ai/ja/aml-mds-gvhd-prevention/Medxy AIja2026-09-16T05:08:04-07:00AML・MDSにおける減量強度同種移植後GVHD予防の最適化：PTCyとATG戦略からみた知見 https://news.medxy.ai/vi/gvhd-prophylaxis-optimization/Medxy AIvi2026-09-16T05:07:47-07:00Tối ưu hóa dự phòng GVHD sau ghép từ người cho phù hợp với điều kiện cường độ giảm ở AML và MDS: Góc nhìn từ chiến lược PTCy và ATG https://news.medxy.ai/optimizing-gvhd-prophylaxis-after-reduced-intensity-matched-donor-transplantation-in-aml-and-mds-insights-from-ptcy-and-atg-strategies/Medxy AIen2026-09-16T05:07:30-07:00Optimizing GVHD Prophylaxis after Reduced-Intensity Matched Donor Transplantation in AML and MDS: Insights from PTCy and ATG Strategies https://news.medxy.ai/zh/pediatric-lymphoma-variants-2/Medxy AIzh2026-09-16T05:06:52-07:00儿童淋巴瘤易感生殖系变异：对诊断年龄与生存结局的影响 https://news.medxy.ai/ja/pediatric-lymphoma-variants/Medxy AIja2026-09-16T05:06:34-07:00小児リンパ腫の発症年齢と予後を左右する生殖細胞系列バリアント https://news.medxy.ai/vi/lymphoma-risk-variants/Medxy AIvi2026-09-16T05:06:16-07:00Biến thể dòng mầm làm tăng nguy cơ lymphoma: tác động lên tuổi chẩn đoán và tiên lượng ở bệnh nhi https://news.medxy.ai/germline-lymphoma-predisposing-variants-influence-on-age-at-diagnosis-and-survival-outcomes-in-pediatric-patients/Medxy AIen2026-09-16T05:05:59-07:00Germline Lymphoma-Predisposing Variants: Influence on Age at Diagnosis and Survival Outcomes in Pediatric Patients https://news.medxy.ai/zh/chop-vs-choep-epoch-2/Medxy AIzh2026-09-16T05:05:19-07:00侵袭性成人T细胞白血病/淋巴瘤中CHOP与CHOEP/EPOCH方案比较：来自国际队列研究的启示 https://news.medxy.ai/ja/adult-t-cell-leukemia-treatment/Medxy AIja2026-09-16T05:05:04-07:00侵襲性成人T細胞白血病／リンパ腫におけるCHOPとCHOEP/EPOCHの比較：国際コホート研究からの知見 https://news.medxy.ai/vi/chop-vs-choep-epoch/Medxy AIvi2026-09-16T05:04:48-07:00So sánh phác đồ CHOP với CHOEP/EPOCH trong u bạch cầu/u lympho tế bào T ở người lớn tiến triển: phát hiện từ một nghiên cứu đoàn hệ quốc tế https://news.medxy.ai/comparing-chop-and-choep-epoch-regimens-in-aggressive-adult-t-cell-leukemia-lymphoma-insights-from-an-international-cohort-study/Medxy AIen2026-09-16T05:04:29-07:00Comparing CHOP and CHOEP/EPOCH Regimens in Aggressive Adult T-Cell Leukemia/Lymphoma: Insights from an International Cohort Study https://news.medxy.ai/zh/cohesin-mutation-role/Medxy AIzh2026-09-16T05:03:52-07:00解开cohesin突变在HLA II类下调与唐氏综合征白血病进展中的作用 https://news.medxy.ai/ja/74214-2/Medxy AIja2026-09-16T05:03:35-07:00ダウン症における白血病の進行およびHLAクラスIIの発現低下におけるコヒーシン変異の役割の解明 https://news.medxy.ai/vi/cohesin-mutation-leukemia/Medxy AIvi2026-09-16T05:03:16-07:00Làm sáng tỏ vai trò của đột biến cohesin trong giảm điều hòa HLA lớp II và tiến triển bệnh bạch cầu ở hội chứng Down https://news.medxy.ai/unraveling-the-role-of-cohesin-mutations-in-hla-class-ii-downregulation-and-leukemia-progression-in-down-syndrome/Medxy AIen2026-09-16T05:02:58-07:00Unraveling the Role of Cohesin Mutations in HLA-Class II Downregulation and Leukemia Progression in Down Syndrome https://news.medxy.ai/ja/tisagenlecleucel-all/Medxy AIja2026-09-16T05:02:21-07:00移植後再発の若年ALL患者におけるティサゲンレクルセル：欧州リアルワールドデータが示す転帰決定因子 https://news.medxy.ai/vi/tisagenlecleucel-relapse-leukemia/Medxy AIvi2026-09-16T05:02:03-07:00Tisagenlecleucel trong tái phát sau ghép ở bệnh nhân bạch cầu lympho cấp trẻ tuổi: các yếu tố quyết định kết cục từ dữ liệu thực tế châu Âu https://news.medxy.ai/tisagenlecleucel-for-post-transplant-relapse-in-young-acute-lymphoblastic-leukemia-patients-european-real-world-determinants-of-outcome/Medxy AIen2026-09-16T05:01:45-07:00Tisagenlecleucel for Post-Transplant Relapse in Young Acute Lymphoblastic Leukemia Patients: European Real-World Determinants of Outcome https://news.medxy.ai/zh/fap-1-deficiency-2/Medxy AIzh2026-09-16T05:01:10-07:00FAP-1缺乏：连接巨核细胞成熟障碍、血小板功能异常与类骨髓纤维化疾病的新机制 https://news.medxy.ai/ja/fap-1-deficiency/Medxy AIja2026-09-16T05:00:52-07:00FAP-1欠損が結ぶ新たな病態連関：巨核球成熟不全、血小板機能障害、骨髄線維症様病態 https://news.medxy.ai/vi/fap-1-deficiency-mekakaryocyte/Medxy AIvi2026-09-16T05:00:34-07:00Thiếu hụt FAP-1: Mối liên kết cơ chế mới với trưởng thành megakaryocyte suy giảm, rối loạn chức năng tiểu cầu và bệnh cảnh giống myelofibrosis https://news.medxy.ai/fap-1-deficiency-a-novel-mechanistic-link-to-impaired-megakaryocyte-maturation-platelet-dysfunction-and-myelofibrosis-like-disease/Medxy AIen2026-09-16T05:00:16-07:00FAP-1 Deficiency: A Novel Mechanistic Link to Impaired Megakaryocyte Maturation, Platelet Dysfunction, and Myelofibrosis-like Disease https://news.medxy.ai/zh/ackr3-cxcr7-thrombosis/Medxy AIzh2026-09-16T04:59:41-07:00靶向 ACKR3/CXCR7：增强血小板抗凝脂质并调控促凝功能，为血栓管理提供新思路 https://news.medxy.ai/ja/ackr3-cxcr7-thrombosis-control/Medxy AIja2026-09-16T04:59:23-07:00ACKR3/CXCR7を標的とした血小板抗凝固性脂質の増強と凝固促進機能の制御：血栓管理への新たな示唆 https://news.medxy.ai/vi/ackr3-cxcr7-thrombosis-2/Medxy AIvi2026-09-16T04:59:04-07:00Nhắm trúng ACKR3/CXCR7: tăng lipid chống đông của tiểu cầu và điều biến chức năng tiền đông máu để kiểm soát huyết khối https://news.medxy.ai/targeting-ackr3-cxcr7-enhances-platelet-anticoagulant-lipids-and-modulates-procoagulant-function-implications-for-thrombosis-management/Medxy AIen2026-09-16T04:58:44-07:00Targeting ACKR3/CXCR7 Enhances Platelet Anticoagulant Lipids and Modulates Procoagulant Function: Implications for Thrombosis Management https://news.medxy.ai/zh/74182-2/Medxy AIzh2026-09-16T04:58:08-07:00重度哮喘早期启动生物制剂治疗：基于全球真实世界队列提升缓解率与临床转归 https://news.medxy.ai/ja/74181-2/Medxy AIja2026-09-16T04:57:52-07:00重症喘息における生物学的製剤の早期導入：世界的なリアルワールド・コホートに基づく寛解および臨床転帰の向上 https://news.medxy.ai/vi/early-biologic-treatment-asthma/Medxy AIvi2026-09-16T04:57:33-07:00Khởi trị sinh học sớm trong hen phế quản nặng: Nâng cao lui bệnh và cải thiện kết cục lâm sàng từ các đoàn hệ thực tế toàn cầu https://news.medxy.ai/early-biologic-initiation-in-severe-asthma-enhancing-remission-and-clinical-outcomes-from-global-real-world-cohorts/Medxy AIen2026-09-16T04:57:13-07:00Early Biologic Initiation in Severe Asthma: Enhancing Remission and Clinical Outcomes from Global Real-World Cohorts https://news.medxy.ai/zh/icu-palliative-care-2/Medxy AIzh2026-09-16T04:56:23-07:00优化ICU姑息照护：专科临床医师对整合与影响的见解 https://news.medxy.ai/ja/icu-palliative-care/Medxy AIja2026-09-16T04:56:09-07:00ICUにおける緩和ケアをどう高めるか：専門医の視点からみた統合と影響 https://news.medxy.ai/vi/palliative-care-icu/Medxy AIvi2026-09-16T04:55:52-07:00Tối ưu hóa chăm sóc giảm nhẹ trong ICU: Góc nhìn từ các bác sĩ chuyên khoa về tích hợp và tác động https://news.medxy.ai/enhancing-palliative-care-in-the-icu-insights-from-specialist-clinicians-on-integration-and-impact/Medxy AIen2026-09-16T04:55:37-07:00Enhancing Palliative Care in the ICU: Insights From Specialist Clinicians on Integration and Impact https://news.medxy.ai/zh/74168-2/Medxy AIzh2026-09-16T04:55:03-07:00ARDS 患者不联合机械通气的体外膜肺氧合治疗：一项国际队列研究的启示 https://news.medxy.ai/ja/74166-2/Medxy AIja2026-09-16T04:54:46-07:00ARDSにおける人工呼吸管理を併用しない体外式膜型人工肺（ECMO）―国際コホート研究からの知見 https://news.medxy.ai/vi/ecmo-no-ventilation-ards/Medxy AIvi2026-09-16T04:54:29-07:00ECMO không thở máy trong ARDS: Góc nhìn từ một nghiên cứu đoàn hệ quốc tế https://news.medxy.ai/extracorporeal-membrane-oxygenation-without-mechanical-ventilation-in-ards-insights-from-an-international-cohort-study/Medxy AIen2026-09-16T04:54:12-07:00Extracorporeal Membrane Oxygenation without Mechanical Ventilation in ARDS: Insights from an International Cohort Study https://news.medxy.ai/zh/asthma-risk-factors-2/Medxy AIzh2026-09-16T04:53:37-07:00从轻至中度到重度哮喘：NORDSTAR队列中的风险因素与患者特征，以及重度哮喘管理新进展 https://news.medxy.ai/ja/asthma-risk-factors-3/Medxy AIja2026-09-16T04:53:16-07:00軽度〜中等度喘息から重症喘息へ：NORDSTARコホートが示す危険因子・患者プロファイルと重症喘息管理の最新進展 https://news.medxy.ai/vi/asthma-risk-factors/Medxy AIvi2026-09-16T04:52:54-07:00Từ hen phế quản nhẹ đến trung bình sang hen phế quản nặng: yếu tố nguy cơ, hồ sơ bệnh nhân từ đoàn hệ NORDSTAR và tiến bộ trong điều trị hen phế quản nặng https://news.medxy.ai/from-mild-to-moderate-to-severe-asthma-risk-factors-and-patient-profiles-from-the-nordstar-cohort-and-advances-in-severe-asthma-management/Medxy AIen2026-09-16T04:52:33-07:00From Mild-to-Moderate to Severe Asthma: Risk Factors and Patient Profiles from the NORDSTAR Cohort and Advances in Severe Asthma Management https://news.medxy.ai/zh/74145-2/Medxy AIzh2026-09-16T04:51:41-07:00激光视网膜固定术后需行额外视网膜干预的风险分层：累积临床因素的影响 https://news.medxy.ai/ja/74143-2/Medxy AIja2026-09-16T04:51:28-07:00網膜光凝固術後の追加的な網膜介入を要するリスクの層別化：累積的な臨床因子の影響 https://news.medxy.ai/vi/retinopexy-risk-stratification/Medxy AIvi2026-09-16T04:51:11-07:00Phân tầng nguy cơ can thiệp võng mạc bổ sung sau laser retinopexy: tác động của các yếu tố lâm sàng cộng dồn